ACE and chronic obstructive pulmonary disease: When introducing the intake of RAAS, ACE inhibitors and beta-blockers into the final model 4 in patients with recent diagnosis of mild to moderate COPD, COPAVP and MRproANP remained statistically significant (p = 0.026 and p = 0,011, respectively).